Results 201 to 210 of about 158,005 (297)

Natural Aging of Biomaterials in Ambient and Physiological Environments

Advanced NanoBiomed Research, EarlyView.
Biomaterials used in biomedical applications can change their physical properties over time, even under ambient and physiological conditions. This review highlights key studies on the natural aging of materials ranging from soft hydrogels to metals and ceramics, emphasizing how time‐dependent changes influence function and performance.
Shuyu Zhang, Anne E. Staples
wiley   +1 more source

Correction to: Optimizing lipid-lowering therapy for acute coronary syndrome using a decision support system: insights from a cluster randomized trial. [PDF]

Eur Heart J Digit Health
europepmc   +1 more source

Cardiovascular risk and lipid-lowering therapy in idiopathic inflammatory myopathies: a call for improved, disease-specific risk assessment. [PDF]

Rheumatol Adv Pract
Loh K, Rose E, Tansley S.
europepmc   +1 more source

Liposomal Delivery of L‐2‐Hydroxyglutarate for Targeting Epigenetic Dysregulation in Osteoarthritis

Advanced NanoBiomed Research, EarlyView.
Osteoarthritis involves cartilage degeneration, inflammation, and epigenetic dysregulation. A liposomal formulation of the TET1 inhibitor L‐2‐hydroxyglutarate to overcome rapid joint clearance was developed. The formulation showed good physicochemical properties, reduced inflammatory and catabolic gene expression in chondrocytes, and alleviated ...
Denise Murgia, Akshay Pandey, Raffaele Spanò, Bianca Martins Estevão, Roberto Palomba, Greta Avancini, Tamaghna Gupta, Ana Maria Lopez Estevez, Stuart B. Goodman, Nidhi Bhutani, Paolo Decuzzi   +10 more
wiley   +1 more source

Lipid-lowering therapy in patients with hypercholesterolemia in terms of the POLSCORE and SCORE2 scales. A single-center retrospective analysis. [PDF]

Cardiol J
Rogozik JK, Grabowski M, Główczyńska R.   +2 more
europepmc   +1 more source

Intensive Lipid-Lowering Therapy Following Acute Coronary Syndrome: The Earlier the Better. [PDF]

J Cardiovasc Dev Dis
Pradhan A, Sharma P, Prajapathi S, Aracri M, Iellamo F, Perrone MA.   +5 more
europepmc   +1 more source

Artificial intelligence-enabled coronary plaque quantification for personalized risk assessment and lipid-lowering therapy: Insights from the FISH&CHIPS study^✰. [PDF]

Am J Prev Cardiol
Parsa S, Peng AW, Bell J, Sengupta S, Mullen S, Rogers C, Nicol ED, Weir-McCall JR, Tidbury L, Martin SS, Fairbairn T, Rodriguez F.   +11 more
europepmc   +1 more source

Echogenicity of carotid plaques as a predictor of regression following lipid-lowering therapy. [PDF]

Thromb J
Fan CH, Hao Y, Chen LF, Cheng J, Wang YQ, Xu LH, Li JM.   +6 more
europepmc   +1 more source

Association of lipid-lowering therapy with dementia and cognitive outcomes: a systematic review and meta-analysis. [PDF]

Age Ageing
Reddin C, Stankard A, Chan KY, Krewer F, Judge C, Canavan M, Davis DHJ, O'Donnell M.   +7 more
europepmc   +1 more source